Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW PEDINOFF

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1033116801
CMS profile
364149
Location
SKILLMAN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$14.87

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $14.87 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $14.87 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW PEDINOFF

NPI 1033116801 · CMS profile ID 364149

Allopathic & Osteopathic Physicians / Allergy & Immunology

SKILLMAN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033116801?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW PEDINOFF, NPI 1033116801, CMS profile ID 364149. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033116801?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ANDREW PEDINOFF, NPI 1033116801, CMS profile ID 364149. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033116801?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ANDREW PEDINOFF, NPI 1033116801, CMS profile ID 364149, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1033116801?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $14.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $14.8702/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736327707 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $14.87 1
PY2021 $2,610.81 21
PY2022 $282.79 24
PY2023 $186.57 18

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $12,078.66 3
PY2023 Principal investigator $155,562.82 28
PY2022 Principal investigator $467,597.19 23
PY2021 Principal investigator $355,310.51 36
PY2020 Principal investigator $554,325.08 51
PY2019 Principal investigator $722,989.71 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,003.75 12/31/2023 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998413521
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,456.81 12/31/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 991127469
Principal investigator 1 ABBVIE INC. $5,585.00 05/04/2023 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RES INC
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998380911
Principal investigator 1 CIPLA USA INC. $4,265.63 04/10/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060138821
Principal investigator 1 CIPLA USA INC. $358.89 04/10/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060138827
Principal investigator 1 CIPLA USA INC. $1,862.31 04/10/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060142921
Principal investigator 1 CIPLA USA INC. $358.89 04/10/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060142927
Principal investigator 1 CIPLA USA INC. $2,426.61 04/10/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060146535
Principal investigator 1 ABBVIE INC. $12,542.52 04/05/2023 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RES INC
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998376765
Principal investigator 1 CIPLA USA INC. $1,205.00 03/23/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060142447
Principal investigator 1 CIPLA USA INC. $1,105.00 03/23/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060142651
Principal investigator 1 ABBVIE INC. $8,567.48 03/09/2023 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RES INC
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998373395
Principal investigator 1 CIPLA USA INC. $1,548.67 03/08/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060144503
Principal investigator 1 CIPLA USA INC. $220.37 03/08/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060146541
Principal investigator 1 CIPLA USA INC. $358.89 02/24/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060143285
Principal investigator 1 CIPLA USA INC. $4,265.63 02/06/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060140911
Principal investigator 1 CIPLA USA INC. $358.89 02/06/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060141745
Principal investigator 1 CIPLA USA INC. $1,862.31 02/06/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060143365
Principal investigator 1 CIPLA USA INC. $358.89 02/06/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060145263
Principal investigator 1 CIPLA USA INC. $1,716.18 02/06/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060145269
Principal investigator 1 CIPLA USA INC. $2,426.61 02/06/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
Not supplied No dispute reported 06/30/2026 1060145339
Principal investigator 1 AstraZeneca Pharmaceuticals LP $49,161.02 02/03/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 991124433
Principal investigator 1 ABBVIE INC. $8,941.24 02/02/2023 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RES INC
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998368333
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,304.14 02/02/2023 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 991125859
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,000.00 01/18/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines No dispute reported 06/30/2026 1017229829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 01/18/2023 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN CAT-ALLERGIC PATIENTS WITH ALLERGIC RHINITIS WHO LIVE WITH A CAT TO ASSESS THE EFFICACY AND SAFETY OF ANTI-FEL D 1 ANTIBODIES DURING NATURAL CAT EXPOSURE IN THE HOME No dispute reported 06/30/2026 977088403
Principal investigator 1 ABBVIE INC. $13,384.34 01/11/2023 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RES INC
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998364963
Principal investigator 1 Novartis Pharmaceuticals Corporation $417.75 01/01/2023 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH CQGE031B2204
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines No dispute reported 06/30/2026 1017192035